Navigation Links
Henry Schein Reports Record First Quarter Results
Date:5/3/2011

penses (70,138)(93,753)Net cash provided by operating activities 47,57921,675Cash flows from investing activities:Purchases of fixed assets (10,458)(9,062)Payments for equity investments and businessacquisitions, net of cash acquired (133,614)(108,946)Purchases of available-for-sale securities -(26,984)Proceeds from sales of available-for-sale securities 2,1001,300Other 1,308(720)Net cash used in investing activities (140,664)(144,412)Cash flows from financing activities:Proceeds from (repayments of) bank borrowings 55,660(931)Proceeds from issuance of long-term debt 3,000-Principal payments for long-term debt (1,526)(1,843)Proceeds from issuance of stock upon exerciseof stock options 18,81415,280Payments for repurchases of common stock(27,098)-Excess tax benefits related to stock-basedcompensation 5,7974,522Distributions to noncontrolling shareholders(1,062)(1,298)Acquisition of noncontrolling interests in subsidiaries(366)(10,000)Other (90)(90)Net cash provided by financing activities 53,1295,640Net change in cash and cash equivalents (39,956)(117,097)Effect of exchange rate changes on cash andcash equivalents 6,3201,331Cash and cash equivalents, beginning of period 150,348471,154Cash and cash equivalents, end of period

$116,712$

355,388Note: Certain prior period amounts have been reclassified to conform to the current presentation.Exhibit AHenry Schein, Inc.2011 First QuarterSales Growth Rate Summary(unaudited)Q1 2011 over Q1 2010ConsolidatedN.A. DentalN.A. MedicalN.A. Animal HealthInternationalTechnology/ VASInternal Sales Growth3.8%2.9%9.9%7.5%-0.1%13.8%Acquisitions6.1%4.3%2.5%4.1%9.9%9.1%Local Currency Sales Growth9.9%7.2%12.4%11.6%9.8%22.9%Foreign Currency Exchange0.7%0.6%0.0%0.0%1.6%0.8%Total Sales Growth10.6%7.8%12.4%11.6%11.4%23.7%Exhibit BHenry Schein, Inc.

2011 First QuarterReconciliation of GAAP results of net income attributable to Henry Schein, Inc. to

non-GAAP results of net income attributable to Henry Schein, Inc.(i
'/>"/>

SOURCE Henry Schein, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Innovative Dental Education Initiative From Henry Schein, ADA And ADEA To Be Featured At ADA Annual Session In Hawaii
2. Henry Schein to Present at the Deutsche Bank Small and Mid Cap Conference
3. Henry Schein to Present at the UBS 20th Annual Global Healthcare Services Conference
4. Henry Schein To Present At The Jefferies 2010 Global Healthcare Services Conference
5. Henry Schein Elects Dr. Bradley T. Sheares to Board of Directors
6. Henry Schein Works With Supplier Partners to Earmark $1 Million in Health Care Supplies for Haiti Earthquake Relief
7. Henry Schein to Present at the NASDAQ OMX 23rd Investor Program
8. Henry Schein Announces New Strategic Partnership With Brain-Pad(R)
9. Henry Schein Announces the Launch of Innovative Henry Schein ConnectHealth(TM) Collaborative
10. Henry Schein Disaster Relief Hotline Stands Ready to Support Dental, Medical and Animal Health Customers
11. Henry Schein to Present at the Goldman Sachs 31st Annual Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... TARRYTOWN, N.Y. , May 21, 2013 ... Inc. (NASDAQ: REGN) today announced that the New ... Phase 2a study results of dupilumab (SAR231893/REGN668) in patients ... antibody targeting the alpha subunit of the interleukin 4 ... and IL-13, drivers of Th2 (Type 2 helper T ...
(Date:5/21/2013)... , May 21, 2013 Abaxis, Inc. (NasdaqGS: ... systems, announced today that Martin Mulroy ... Stifel Annual Dental & Veterinary Conference on Wednesday, May ... be held at Le Parker Meridien Hotel in ... Abaxis Abaxis develops, manufactures, markets and sells ...
(Date:5/21/2013)... 2013 Reportlinker.com announces that a ... its catalogue:   ... Medical Devices in the US Market ... Changing Regulatory and Reimbursement Scenario for ...   Summary ...
Breaking Medicine Technology:Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 3Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 4
... 10, 2011 Sanofi-aventis (EURONEXT: SAN and ... (Nasdaq: REGN ) today announced results from ... aflibercept (VEGF Trap) for the second-line treatment of non-small ... aflibercept to the chemotherapy drug docetaxel did not meet ...
... 2011 Transgenomic, Inc. (OTC Bulletin Board: TBIO ) ... December 31, 2010, and provided a business update. The ... $0.06 per share, compared with a net loss for 2009 of ... $20.0 million, compared with $22.0 million for 2009.  Gross profit was ...
Cached Medicine Technology:Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 2Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 3Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 4Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 5Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 6Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 7Transgenomic Reports Fourth Quarter Financial Results 2Transgenomic Reports Fourth Quarter Financial Results 3Transgenomic Reports Fourth Quarter Financial Results 4Transgenomic Reports Fourth Quarter Financial Results 5Transgenomic Reports Fourth Quarter Financial Results 6Transgenomic Reports Fourth Quarter Financial Results 7
(Date:5/21/2013)... 21, 2013 According to a May 13, ... Use of Botox,” Botox injections have become the ... in 2002 (Go to goo.gl/8iYbD). Although it is mostly associated ... men. The injection makes facial wrinkles less visible by paralyzing ... for about three months. This means that people who are ...
(Date:5/21/2013)... Diversity Focus, a non-profit organization striving to ... in the Creative Corridor region, is releasing results for ... conference on Thursday, May 23rd at 10:30 a.m. ... , The survey is a critical component ... that attract, nurture and retain people of diverse backgrounds, ...
(Date:5/21/2013)... (May 21, 2013) A paper recently published in ... co-written by physicians and scientists at the University of ... risk factor for pulmonary fibrosis can be used to ... , Researchers looked at a fairly common variant of ... component of the mucous produced by the bronchial tubes. ...
(Date:5/21/2013)... for scientific and technological research So Paulo Research Foundation, ... an investment estimated in US$ 680 million to support ... period of up to eleven years, subject to continuation ... Funding for the 17 RIDCs will come from FAPESP ... personnel, and infrastructure). Host institutions will participate in a ...
(Date:5/21/2013)... Park City, Utah (PRWEB) May 21, 2013 ... on HRA, HSA and FSA accounts. Zane ... employer sponsored health benefits, is the leader in ... health reimbursement arrangements . , According to Zane ... or health reform) was signed into law in 2010 ...
Breaking Medicine News(10 mins):Health News:Botox – Is the World’s Most Popular Cosmetic Procedure Safe? 2Health News:Diversity Focus Announces Results from 2013 Creative Corridor Survey at News Conference on Thursday, May 23rd at 10:30 a.m. 2Health News:Researchers find genetic risk factor for pulmonary fibrosis 2Health News:Research at the cutting edge of knowledge 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 3
... rates of hospital use, but they may be experiencing ... said in the latest edition of the Medical ... Melbourne-based Refugee Health Research Centre, Dr Ignacio Correa-Velez, and ... financial years to June 2004. ,'We found ...
... -- The science has long been clear that smoking causes ... damage from a father who smokes . ,Canadian ... in the DNA sequence of sperm cells, alterations that could ... are published in the June 1 issue of Cancer Research, ...
... market is estimated at around $2.5 trillion per annum, ... percent per annum. A radical shift in food consumption ... ,In markets, especially in the developed world, with ... is rapidly increasing. Besides, the emerging health-conscious newer generation ...
... released by a growing tumor could one day become ... chemotherapy and radiation treatment in people with advanced throat ... 1, 2007, issue of Clinical Cancer Research. ... Communication Disorders (NIDCD) and National Cancer Institute (NCI), two ...
... Researchers have found that patients with obstructive sleep apnea ... dead cells (apoptotic cells) from the lining (endothelium) of ... who do not have OSA. The finding may help ... for cardiovascular disease (CVD). ,According to the ...
... In a retrospective study of 700 patients with ... be significantly higher in HIV-infected patients compared ... TB relapse rates were higher in HIV-infected patients ... compared to those receiving daily or longer treatment. ...
Cached Medicine News:Health News:Cigarette Smoke Alters DNA in Sperm, Genetic Damage Could Pass to Offspring 2Health News:Nutrient-rich Dairy Beverages an Emerging Market 2Health News:Blood Test may Help Signal Tumor's Remission, Return in Throat Cancer Patients 2Health News:Blood Test may Help Signal Tumor's Remission, Return in Throat Cancer Patients 3Health News:Blood Test may Help Signal Tumor's Remission, Return in Throat Cancer Patients 4Health News:Patients With OSA at Higher Risk for Cardiovascular Disease 2Health News:Patients With OSA at Higher Risk for Cardiovascular Disease 3Health News:Treatment Outcomes of Patients With HIV and Tuberculosis 2
Inquire...
Remote Blower With Bag-In/Bag-Out Option...
Class II Type B2 Biological Safety Cabinet...
Class II Type A2 Biological Safety Cabinet...
Medicine Products: